Jan 25th 2013 - Edison Investment Research today published a report on quickview entitled "Wherefore Art Thou Romo". In summary, the report says:
Much attention rests on UCB’s three recently launched drugs but forthcoming news regarding its Phase III, Amgen-partnered antibody, romosozumab, could help to maintain the current share price momentum. Phase II data show a rapid increase in bone mineral density (BMD) in women with post-menopausal osteoporosis (PMO) that is superior to existing therapies, with no concerning safety signals. Data from the ongoing Phase III trials assessing c 10,000 women with PMO are not expected until 2015. However, new fracture healing data, expected in H113 and Phase III trial initiations, expected this year could provide further indication of its potential.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »